×
DexCom Common Stock Net 2010-2024 | DXCM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
DexCom common stock net for the quarter ending June 30, 2024 was
$0.000B
, a
0% increase
year-over-year.
DexCom common stock net for 2023 was
$0B
, a
0% decline
from 2022.
DexCom common stock net for 2022 was
$0B
, a
0% decline
from 2021.
DexCom common stock net for 2021 was
$0B
, a
300% increase
from 2020.
View More
DexCom Common Stock Net 2010-2024 | DXCM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
DexCom common stock net for 2023 was
$0B
, a
0% decline
from 2022.
DexCom common stock net for 2022 was
$0B
, a
0% decline
from 2021.
DexCom common stock net for 2021 was
$0B
, a
300% increase
from 2020.
Related Stocks
Company Name
Market
Cap
Thermo Fisher Scientific (TMO)
$233.2B
Intuitive Surgical (ISRG)
$171.7B
Alcon (ALC)
$47.9B
IQVIA Holdings (IQV)
$43.7B
IDEXX Laboratories (IDXX)
$42.2B
Edwards Lifesciences (EW)
$40.5B
STERIS (STE)
$23.8B
SONOVA HOLDING (SONVY)
$21.2B
Waters (WAT)
$19.5B
Hologic (HOLX)
$19B
Sysmex ADR (SSMXY)
$12.6B
Fresenius Medical Care AG KGaA (FMS)
$12.3B
Teleflex (TFX)
$11.4B
Globus Medical (GMED)
$9.4B
Penumbra (PEN)
$7.3B
Glaukos (GKOS)
$6.7B
Masimo (MASI)
$6.1B
TransMedics (TMDX)
$5.2B
Integer Holdings (ITGR)
$4.2B
PROCEPT BioRobotics (PRCT)
$4.1B
Tandem Diabetes Care (TNDM)
$2.8B
LivaNova (LIVN)
$2.8B
Veracyte (VCYT)
$2.6B
Inari Medical (NARI)
$2.6B
Elekta AB (EKTAY)
$2.5B
Nihon Kohden (NHNKY)
$2.5B
RxSight (RXST)
$2.1B
Integra LifeSciences Holdings (IART)
$1.3B
Pulse Biosciences (PLSE)
$1.2B
OPKO Health (OPK)
$1.2B